Research Analysts’ Recent Ratings Updates for AstraZeneca (AZN)

A number of firms have modified their ratings and price targets on shares of AstraZeneca (NYSE: AZN) recently:

• 10/31/2026 – AstraZeneca was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/26/2026 – AstraZeneca was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 10/13/2026 – AstraZeneca was upgraded by Nordea Equity Research from “sell” to “buy”.
• 10/13/2026 – AstraZeneca was upgraded by Zacks Research from “strong sell” to “hold”.
• 10/11/2026 – AstraZeneca was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/6/2026 – AstraZeneca had its “buy” rating reaffirmed by Citigroup.
• 10/3/2026 – AstraZeneca was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/15/2026 – AstraZeneca was upgraded by Deutsche Bank Aktiengesellschaft from “sell” to “hold”.
• 9/14/2026 – AstraZeneca was downgraded by Zacks Research from “hold” to “strong sell”.
• 9/8/2026 – AstraZeneca is now covered by Royal Bank Of Canada. They set an “outperform” rating on the stock.

AstraZeneca Trading Down 1.5%

AZN stock traded down $2.79 on Tuesday, reaching $183.79. The company’s stock had a trading volume of 3,682,124 shares, compared to its average volume of 2,838,169. The business has a fifty day simple moving average of $164.90 and a two-hundred day simple moving average of $180.18. AstraZeneca Plc has a 12-month low of $153.41 and a 12-month high of $212.71. The firm has a market cap of $285.04 billion, a PE ratio of 26.00, a PEG ratio of 1.31 and a beta of 0.27. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.67 and a current ratio of 0.89.

AstraZeneca (NYSE:AZN) last issued its quarterly earnings data on Friday, October 30th. The company reported $2.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a net margin of 17.02% and a return on equity of 31.45%. The business had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. During the same period in the previous year, the firm earned $2.38 EPS. The company’s quarterly revenue was up 6.5% compared to the same quarter last year. As a group, research analysts forecast that AstraZeneca Plc will post 10.21 EPS for the current year.

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.